Novel therapies for memory cells in autoimmune diseases

Research output: Contribution to journalArticle

Abstract

Autoimmune diseases are a major cause of morbidity, and their incidence and prevalence continue to rise. Treatments for these diseases are non-specific and result in significant adverse effects. Targeted therapies may help in improving the risk : benefit ratio associated with treatment. Immunological memory is an important feature of the vertebrate immune system that results in the production of cells that are long-lived and able to respond to antigens in a more robust manner. In the setting of autoimmunity this characteristic becomes detrimental due to the ongoing response to a self-antigen(s). These memory cells have been shown to play key roles in various autoimmune diseases such as type 1 diabetes, multiple sclerosis and psoriasis. Memory T cells and B cells can be identified based on various molecules expressed on their surface. Memory T cells can be divided into three main categories - central memory, effector memory and resident memory cells. These subsets have different proliferative potential and cytokine-producing abilities. Utilizing differentially expressed surface molecules or downstream signalling pathway proteins in these cells it is now possible to target memory cells while sparing naive cells. We will discuss the various available options for such a strategy and several potential strategies that may yield successful therapies in the future.

Original languageEnglish (US)
Pages (from-to)353-360
Number of pages8
JournalClinical and Experimental Immunology
Volume180
Issue number3
DOIs
StatePublished - Jun 1 2015

Fingerprint

Cell- and Tissue-Based Therapy
Autoimmune Diseases
Immunologic Memory
T-Lymphocytes
Aptitude
Autoantigens
Therapeutics
Autoimmunity
Type 1 Diabetes Mellitus
Psoriasis
Multiple Sclerosis
Vertebrates
Immune System
B-Lymphocytes
Odds Ratio
Cytokines
Morbidity
Antigens
Incidence
Proteins

Keywords

  • Autoimmune disease
  • Immunological memory
  • Memory B cell
  • Memory T cell
  • Targeted therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Novel therapies for memory cells in autoimmune diseases. / Bhargava, Pavan; Calabresi, Peter.

In: Clinical and Experimental Immunology, Vol. 180, No. 3, 01.06.2015, p. 353-360.

Research output: Contribution to journalArticle

@article{451c268bfc534eeb90c27ca5250c5c16,
title = "Novel therapies for memory cells in autoimmune diseases",
abstract = "Autoimmune diseases are a major cause of morbidity, and their incidence and prevalence continue to rise. Treatments for these diseases are non-specific and result in significant adverse effects. Targeted therapies may help in improving the risk : benefit ratio associated with treatment. Immunological memory is an important feature of the vertebrate immune system that results in the production of cells that are long-lived and able to respond to antigens in a more robust manner. In the setting of autoimmunity this characteristic becomes detrimental due to the ongoing response to a self-antigen(s). These memory cells have been shown to play key roles in various autoimmune diseases such as type 1 diabetes, multiple sclerosis and psoriasis. Memory T cells and B cells can be identified based on various molecules expressed on their surface. Memory T cells can be divided into three main categories - central memory, effector memory and resident memory cells. These subsets have different proliferative potential and cytokine-producing abilities. Utilizing differentially expressed surface molecules or downstream signalling pathway proteins in these cells it is now possible to target memory cells while sparing naive cells. We will discuss the various available options for such a strategy and several potential strategies that may yield successful therapies in the future.",
keywords = "Autoimmune disease, Immunological memory, Memory B cell, Memory T cell, Targeted therapy",
author = "Pavan Bhargava and Peter Calabresi",
year = "2015",
month = "6",
day = "1",
doi = "10.1111/cei.12602",
language = "English (US)",
volume = "180",
pages = "353--360",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Novel therapies for memory cells in autoimmune diseases

AU - Bhargava, Pavan

AU - Calabresi, Peter

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Autoimmune diseases are a major cause of morbidity, and their incidence and prevalence continue to rise. Treatments for these diseases are non-specific and result in significant adverse effects. Targeted therapies may help in improving the risk : benefit ratio associated with treatment. Immunological memory is an important feature of the vertebrate immune system that results in the production of cells that are long-lived and able to respond to antigens in a more robust manner. In the setting of autoimmunity this characteristic becomes detrimental due to the ongoing response to a self-antigen(s). These memory cells have been shown to play key roles in various autoimmune diseases such as type 1 diabetes, multiple sclerosis and psoriasis. Memory T cells and B cells can be identified based on various molecules expressed on their surface. Memory T cells can be divided into three main categories - central memory, effector memory and resident memory cells. These subsets have different proliferative potential and cytokine-producing abilities. Utilizing differentially expressed surface molecules or downstream signalling pathway proteins in these cells it is now possible to target memory cells while sparing naive cells. We will discuss the various available options for such a strategy and several potential strategies that may yield successful therapies in the future.

AB - Autoimmune diseases are a major cause of morbidity, and their incidence and prevalence continue to rise. Treatments for these diseases are non-specific and result in significant adverse effects. Targeted therapies may help in improving the risk : benefit ratio associated with treatment. Immunological memory is an important feature of the vertebrate immune system that results in the production of cells that are long-lived and able to respond to antigens in a more robust manner. In the setting of autoimmunity this characteristic becomes detrimental due to the ongoing response to a self-antigen(s). These memory cells have been shown to play key roles in various autoimmune diseases such as type 1 diabetes, multiple sclerosis and psoriasis. Memory T cells and B cells can be identified based on various molecules expressed on their surface. Memory T cells can be divided into three main categories - central memory, effector memory and resident memory cells. These subsets have different proliferative potential and cytokine-producing abilities. Utilizing differentially expressed surface molecules or downstream signalling pathway proteins in these cells it is now possible to target memory cells while sparing naive cells. We will discuss the various available options for such a strategy and several potential strategies that may yield successful therapies in the future.

KW - Autoimmune disease

KW - Immunological memory

KW - Memory B cell

KW - Memory T cell

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84929514280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929514280&partnerID=8YFLogxK

U2 - 10.1111/cei.12602

DO - 10.1111/cei.12602

M3 - Article

C2 - 25682849

AN - SCOPUS:84929514280

VL - 180

SP - 353

EP - 360

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -